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The herb medicine formula “Chong Lou Fu Fang” (CLFF) has eﬃcacy in inhibiting the proliferation of human gastric cancer
in vitro and in vivo. To explore the potentially useful combination of CLFF with chemotherapeutic agents commonly used in
gastric cancer therapy, we assess the interaction between CLFF and these chemotherapeutic agents in both SGC-7901 cell lines
and BGC-823 cell lines using a median eﬀect analysis and apoptosis analysis, and we also investigate the inﬂuence of CLFF on
chemotherapeutic agent-associated gene expression. The synergistic analysis indicated that CLFF had a synergistic eﬀect on the
cytotoxicity of5-ﬂuorouracil(5-FU) in a relative broad dose inhibitionrange (20–95%fraction aﬀected in SGC-7901cell lines and
5–65% fraction aﬀected in BGC-823 cell lines), while the synergistic interaction between CLFF and oxaliplatin or docetaxel only
existed in a low dose inhibition range (≤50% fraction aﬀected in both cell lines). Combination of CLFF and chemotherapeutic
agents could also induce apoptosis in a synergistic manner. After 24 h, CLFF alone or CLFF combination with chemotherapeutic
agents could signiﬁcantly suppress the levels of expression of chemotherapeutic agent resistance related genes in gastric cancer
cells. Our ﬁndings indicate that there are useful synergistic interactions between CLFF and chemotherapeutic agents in gastric
cancer cells, and the possible mechanisms might be partially due to the down-regulation of chemotherapeutic agent resistance
related genes and the synergistic apoptotic eﬀect.
1.Introduction
Despite its declining incidence, gastric cancer is still the
second most common cause of death from cancer in Asia
and worldwide [1, 2]. Surgery remains the mainstay of
any curative treatment; however, approximately two-thirds
of patients diagnosed with gastric cancer have unresectable
locally advanced and/or metastatic disease [3]. Most patients
with advanced gastric cancer need to accept cytotoxic
chemotherapy as one of main treatments. Recently, plat-
inum compounds, 5-ﬂuorouracil and taxanes have been
widely used in treatment of gastric cancer. Various attempts
have been made to improve the objective response rate
to chemotherapy, including chemotherapeutic agents in
combination, however, the optimal combination regimen
has remained elusive, and standard treatment remains a
matter of debate [4]. It is necessary to ﬁnd new compounds
and optimized combinational treatment for gastric cancer.
Herb medicine as complementary and alternative ther-
apy (CAM) has enjoyed a growing popularity in cancer
patients as a less intensive and more natural approach to
alleviating the side eﬀects of chemotherapy or improving
quality of life [5–7]. And more and more cancer patients
select herb medicine as CAM in combination with their con-
ventional chemotherapeutic treatment [8], which increases
the probability of clinically relevant herb-chemotherapeutic2 Evidence-Based Complementary and Alternative Medicine
agents interactions. Considering the narrow therapeutic
window of chemotherapeutic agents, the synergistic or
additive interactions may increase the outcomes of the ther-
apy and decrease the dosages of chemotherapeutic agents.
CLFF is a prescribed complex of Chinese herbal formula
containing three ingredients as follows: Rhizoma Paridis,
Fructus Forsythiae and Radix Codonopsis,i nw h i c hR. Paridis
represents the principal ingredient, while F. Forsythiae and
R. Codonopsis serve as adjuvant ones to assist the eﬀects
of R. Paridis. In traditional Chinese medicine (TCM), R.
Paridis as principal component of many herbal formulae
has been widely used as CAM in various kinds of cancers,
such as gastric cancer, lung cancer, hepatic carcinoma,
cervical cancer and so on [9]. Because of diﬀerent adjuvant
components, every formula has a diﬀerent name or no
name,andprecisemechanisms oftheseformulaealsoremain
to be addressed by using molecular approaches. CLFF as
one of those formulae is being studied in our laboratory,
and two components of CLFF, R. Paridis and F. Forsythiae
have been proved to have potential anticancer activity on
digestive cancer in our preliminary experiment [10, 11], and
R. Codonopsis, another component of CLFF, has also long
been used for replenishing energy deﬁciency, strengthening
the immune system, lowering blood pressure and improving
appetite in China [12]. In vitro and in vivo studies have
indicated that CLFF has prominent cytotoxic eﬀect and
potential immune-modulating function on many kinds of
gastrointestinal cancers, but not has signiﬁcant side eﬀects
(another parallel study). However, the potential role of this
formula in cancer therapy has not been clearly addressed by
modern science.
This preclinical study was therefore undertaken to
investigate whether combination of CLFF and a series of
chemotherapeutic agents could result in a useful synergistic
interaction against gastric cancer cells. To elucidate fur-
ther the mechanisms possibly involved in the interaction
between the CLFF and chemotherapeutic agents, we also
investigated apoptosis and expression of chemotherapeutic
agent resistance related genes in gastric cancer cells after
treatment with CLFF and chemotherapeutic agents singly
and in combination.
2.Methods
2.1. Preparation of CLFF Extract. Medicinal plants were pro-
vided by Nanjing herb Pharmaceutics Ltd. (Nanjing, China)
for the preparation of the CLFF extract. The preparation
is a mixture of three crude plant extract ingredients: R.
Paridis, F. Forsythiae and R. Codonopsis,a tar a t i oo f1 0:5:5 .
The plants were homogenized with a Waring blender, then
soaked in 10l (10-fold of the plant) double distilled water
(DDW) for 24h. The mixture was heated to 100◦Cf o r1h ,
and the decoction was ﬁltrated. The ﬁltrates obtained from
three cycles of the procedures were mixed, concentrated by
heating and granulated by lyophilization. Total yield of the
CLFF extract is 125g lyophilized powder from water extract
of 1kg raw mixed herb. Aqueous solution was prepared
by dissolving the granulated formulae in water at 250mg
Table 1: The component of CLFF.
Species (family) Chinese name Plant part Origin
Rhizoma Paridis Chong lou Stem Yunnan, China
Fructus Forsythiae Lian qiao Fruit Anhui, China
Radix Codonopsis Dang shen Root Sichuan, China
Table 2: The IC50 doses of CLFF and chemotherapeutic agents.
Cell line IC50 (mean ± SD)
CLFF
(mgml−1)
5-Fluorouracil
(μm)
Oxaliplatin
(μm)
Docetaxel
(μm)
SGC-7901 0.22 ± 0.03 42.81 ± 0.03 64.51 ± 4.49 2.74 ± 0.45
BGC-823 0.72 ± 0.06 196.28 ± 33.07 32.41 ± 2.39 17.02 ± 0.91
raw mixed herb/ml for CLFF and ﬁltered through a 0.2mm
ﬁlter (Microgen, Laguna Hills, CA, USA) before use. The
quality control on CLFF preparation, including deﬁnition
of the correct plants, origin of production, implantation,
harvesting and processing, was according to the guidelines
deﬁned by Chinese State Food and Drug Administration
(SFDA). The species, plant parts and origin used in the
formula as Table 1.
2.2. Cell Lines and Cell Culture. Human poorly diﬀeren-
tiated SGC-7901 cells was kindly provided by the center
laboratory of the Second Hospital, Chang Zhou (China),
BGC-823 cells was obtained from Shanghai Institute of Cell
Biology (Shanghai, China). All cell lines were propagated
in RPMI 1640 medium (GIBCO BRL), supplemented with
10% bovine serum, penicillin (100Uml−1)—streptomycin
(100μgml −1), pyruvate, glutamine and insulin at 37
◦Ci na
water-saturated atmosphere with 5% CO2.
2.3. Drugs. 5-Fluorouracil (5-FU), oxaliplatin (Oxa) and
docetaxel (Doc) were supplied from Jiangsu Hengrui
Medicine Company (Jiangsu, China). The dilutions of all of
the reagents were freshly prepared before each experiment.
CellTiter 96 AQueous One Solution Cell Proliferation Assay
kit was purchased from Promega (Madison, WI, USA).
Annexin-V-FITC Apoptosis Detection Kit was purchased
from Invitrogen (Carlsbad, CA, USA).
2.4. Cytotoxicity Assay and Analysis of Combination Eﬀects.
Cytotoxicity was determined by CellTiter 96 AQueous One
Solution Cell Proliferation Assay kit. Brieﬂy, Tumor cells
growing in log-phase were trypsinized and seed at 2 ×
103 cells per well into 96-well plates and allowed to attach
overnight. Medium in each well was replaced with fresh
medium or medium with various concentrations of drug
in at least six replicate wells and left contact for 48h.
One–ﬁfth volume of CellTiter 96 AQueous One Solution
was added to each well and incubated for an additional
3h, Absorbance was determined with a microplate reader
(BIO-RAD) at 490nm. The blank control wells were used
for zeroing absorbance. Each experiment was allocated 10-
wells containing drug-free medium for the control. TheEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Dose-response curve of CLFF and chemotherapeutic agents singly or in combination for SGC-7901 (a–c) and BGC-823 (d–f)
cells. Data point, means of at least three independent experiment; bars, SD, standard deviation.
inhibition rate (I%) was calculated using the background-
corrected absorbance by the following equation: I% = 100 ×
(Auntreated control well − Aexperimental well)/Auntreated control well.T h e
IC50 was deﬁned as the concentration required for 50%
inhibition of cell growth.
For the combination experiments, drugs were added
either concomitantly or sequentially with seven diﬀerent
concentrations of the single agent and seven diﬀerent
concentrations of both agents at their ﬁxed concentration
ratio for 48h. The fractional inhibition of cell proliferation4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Combination index values for simultaneous treatment of CLFF and chemotherapeutic agents in SGC-7901 (a–c) and BGC-823
(d–f) cells. Cells were simultaneously exposed to two agents at ﬁxed ratios for 48 h at 37
◦Ci n5 %C O 2. Data point, means of at least three
independent experiment; bars, SD; (a, d) CLFF plus 5-ﬂuorouracil; (b, e) CLFF plus oxaliplatin; (c, f) CLFF plus docetaxel. CI < 1, =1a n d
>1 indicate synergism, addition and antagonism,respectively.
Table 3: Summary of CI values at 20, 50 and 80% fraction aﬀected.
Cell line Regimen CI at fraction aﬀected (mean ± SD)
20% 30% 50% 80%
SGC-7901 CLFF + 5-FU 0.80 ± 0.18 0.68 ± 0.06 0.71 ± 0.03 0.79 ± 0.02
CLFF + Oxa 0.87 ± 0.21 0.98 ± 0.15 1.22 ± 0.07 1.80 ± 0.42
CLFF + Doc 0.68 ± 0.22 0.78 ± 0.17 0.98 ± 0.12 1.55 ± 0.41
BGC-823 CLFF + 5-FU 0.69 ± 0.11 0.74 ± 0.06 0.85 ± 0.02 1.15 ± 0.15
CLFF + Oxa 0.90 ± 0.19 0.99 ± 0.16 1.21 ± 0.07 1.63 ± 0.18
CLFF + Doc 0.74 ± 0.23 0.90 ± 0.23 1.24 ± 0.22 2.06 ± 0.15Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Combination index values with the treatment schedule chemotherapeutic agents preceding CLFF in SGC-7901 (a–c) and BGC-
823 (d–f) cells. Cells were pretreated with every chemotherapeutic agent for 24h, followed by CLFF at ﬁxed ratios for 48h at 37
◦Ci n5 %
CO2. Data point, means of at least three independent experiment; bars, SD; (a, d) CLFF plus 5-ﬂuorouracil; (b, e) CLFF plus oxaliplatin; (c,
f) CLFF plus docetaxel. CI < 1, =1a n d>1 indicate synergism, addition and antagonism,respectively.
was calculated by comparison to control cultures. Dose-
response curves were obtained for each drugs, and for
multiple dilutions of a ﬁxed-ratio combination of the two
drugs. Median eﬀect analysis using the combination index
(CI) method of Chou and Talalay [13] was employed to
determine the nature of the interaction observed between
CLFF and chemotherapeutic agents. The CI is deﬁned by
the following equation: CI = (D)1/(Dx)1 + (D)2/(Dx)2 +
α(D)1(D)2/(Dx)1(Dx)2,i nw h i c h( Dx)1 and (Dx)2 are the
concentrations for D1 (CLFF) and D2 (chemotherapeutic
agent) alone that gives x% inhibition, whereas (D)1 and
(D)2 in the numerators are the concentrations of CLFF and
another drug that produce the identical level of eﬀect in
combination. α = 0 when the drugs are mutually exclusive
(i.e., with similar modes of action), while α = 1 when they
are mutually non-exclusive (i.e., with independent modes of
action).CIs>1indicateantagonism,CIs<1indicatesynergy
andCIs=1indicateadditivity.EachCIratiorepresentedhere
is the mean value derived from at least three independent
experiments.
2.5. Apoptosis Assay. Cells quantiﬁcation of apoptosis cells
was performed using an Annexin-V-FITC Apoptosis Detec-
tion Kit (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Brieﬂy,cellswere platedin a 60-
mm Petri disk and allowed to grow to 75–80% conﬂuence.
They were exposed to CLFF and anticancer drugs added
singly or in combination for 48h and compared with control
cells not treated with drugs. Then cells were collected and
resuspended in 500μlo fb i n d i n gb u ﬀer,and 5μl of Annexin-
V-ﬂuorescein isothiocyanate (FITC) and 5μl of propidium
iodide (PI)were added. Analyses were performed with a ﬂow6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: CLFF treatment increase chemotherapeutic agent-induced apoptosis in SGC-7901 (a–h) and BGC-823 (i–p) cells. (a, i) both cell
lines were treated without drug. (b, j) both cell lines were treated with CLFF alone. (c, k) both cell lines were treated with 5-ﬂuorouracil
alone.(d,l) both cell lines were treated withCLFF combinationwith5-ﬂuorouracil.(e,m) both cell lines were treated withoxaliplatinalone.
(f, n) both cell lines were treated with CLFF combinationwith oxaliplatin.(g, o) both cell lines were treated with docetaxel alone. (h, p) both
cell lines were treated with CLFF combination with docetaxel. Early apoptotic cells were deﬁned as Annexin-V-positive, PI-negative cells,
late apoptotic cells were deﬁned as Annexin-V-positive, PI-positive cells.Evidence-Based Complementary and Alternative Medicine 7
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Figure 5: Eﬀect of CLFF on the expression of chemotherapeutic
agent resistance-related genes in SGC-7901 cells. The level of
ERCC1, TS, β-tubulin III and tau mRNA expression, followed
treatment with CLFF and every chemotherapeutic agent singly at
their respective IC40 or in combination for 24 h, was determined
in SGC-7901 cells by real-time RT-PCR. a1: cells were treated with
5-ﬂuorouracil alone. a2: cells were treated with oxaliplatin alone.
a3: cells were treated with docetaxel alone. b1: cells were treated
with CLFF combination with 5-ﬂuorouracil. b2: cells were treated
with CLFF combinationwith oxaliplatin.b3: cells were treated with
CLFF combination with docetaxel. Data point, means of at least
three independent experiment; bars, SD.
∗P<. 05 versus control
cells.
cytometer (FACScalibur, Becton Dickinson, Franklin Lakes,
NJ, USA).
2.6.QuantitativeRT-PCR. Cellswereharvestedwithtrypsin,
washed with PBS, and collected by centrifugation at
1000rpm for 5min. Total RNA was extracted using SV
Total RNA isolation system (Promega, Madison, WI, USA)
following the manufacturer’s protocol. And its purity and
quality were measured by Bio-visible spectrophotometer
(Eppendorf, Germany); 1% agarose gel electrophoresis was
used to assess the integrity of the obtained RNA. cDNA
with a total volume of 20μl was synthesized using the
reverse transcription system containing reverse transcriptase
(Promega, Madison, WI, USA) according to the recom-
mended protocol by the manufacturer. Real-time quan-
titative PCR of the target gene and β-actin as internal
control was carried out with icycler iQ Multicolor Real-
time PCR Detection System (Bio-Rad Laboratories, Inc.).
The 20μl PCR reaction mixture contained 1× primers
and probe mixture (Applied Biosystems, Foster city, CA.
Assay IDs: Hs00157415 m1 (ERCC1); Hs00426591 m1
(TS); Hs00964965 m1 (β-tubulin III); Hs00213491 m1
(tau); Hs99999903 m1 (β-actin)), 1× Absolute QPCR Mix
(ABgene, Surrey, UK). The PCR conditions were 50
◦Cf o r2
min, 95
◦C for 15min, followed by 45 cycles at 95
◦Cf o r1 5s
and 60
◦C for 1min. Relative gene expression quantiﬁcations
were calculated according to the comparative CT method
using β-actin as an endogenous control and commercial
human total RNA (BD Clontech, CA, USA) as calibrators.
Final results were determined by the formula2−ΔΔCT method
[14].
2.7. Statistical Analysis. Values were expressed as means ±
standard deviations. Statistical comparison was performed
using Student’s t-test, and a P-value of <.05 was considered
statistically signiﬁcant.
3.Results
3.1. Cytotoxicities of CLFF and Chemotherapeutic Agents
against SGC-7901 and BGC-823 Cells. The cytotoxic activ-
ities of CLFF and chemotherapeutic agents were tested
individually on both two cell lines. As expected, CLFF
and each chemotherapeutic agent individually increased the
cytotoxicity of both two cell lines in a dose-dependent
fashion. Table 2 shows the IC50 doses for both SGC-7901
and BGC-823 cells lines following exposure to CLFF or
chemotherapeutic agents. The response of both two cells
lines to these drugs was signiﬁcantly diﬀerent (P < .05). And
it appeared that SGC-7901 cells was more sensitive to CLFF,
5-FU and Doc, while BGC-823 cells was more sensitive to
Oxa, suggesting the genetic make-up of the cells plays an
important role in the response to drug treatment.
3.2. Median-Eﬀect Analysis of CLFF and Chemotherapeutic
Agent Combination In Vitro. To explore whether CLFF could
enhance the eﬀects of the chemotherapeutic agents currently
used to treat gastric cancer, the eﬀects of 48h treatment
with CLFF, 5-FU, Oxa and Doc singly and in combination
were examined. Figure 1 shows the dose-response curves for
SGC-7901 and BGC-823 cells lines exposed to CLFF and
chemotherapeutic agents singly and in combination. For
both cell lines, drug combinations gave a more intensive
inhibition of cell proliferation. Especially combination of
5-FU and CLFF resulted in more eﬀective inhibition of
cell proliferation in almost all range of inhibition rates. To
fully evaluate the nature of the interaction between CLFF
and chemotherapeutic agents, we analyzed the combination
of both drugs using media-eﬀect analysis, which resolves
the degree of synergy, addictively, or antagonism at various
levels of cell death. Figure 2 illustrates the multiple drug
eﬀect obtained for SGC-7901 and BGC-823 cells, which
were treated simultaneously with CLFFand anticancer drugs
and represented as fractional cell growth inhibition (FA)
as a function of the CI. As shown in Figure 2,w h e nc e l l s
were treated with CLFF and 5-FU simultaneously, the CI
values were below 1 in a relative broad range of killed cell
fraction in both cell lines, which indicated that CLFF had
as y n e r g i s t i ce ﬀect on the cytotoxicity of 5-FU in a more
broad range of dose inhibition rate. While combination
of CLFF and other two chemotherapeutic agents resulted
in synergistic eﬀects only at lower levels of killed cell
fraction in both cell lines (<50% killed cell fraction). The
results are summarized in Table 3, which shows, for each
combination, the computer-calculated CI for 20, 30, 50
and 80% cytotoxicity (Fa = 0.2, 0.3,0.5, 0.8, resp.). It was
diﬀerent in some extent of concentrations between two cell8 Evidence-Based Complementary and Alternative Medicine
lines. But in all combinations, the CI values were below 1
at Fa = 0.3, indicating a synergistic anti-proliferative eﬀect
at lower levels of killed cell fraction. We also evaluated
the eﬀects of sequential drug exposure, in which either
CLFF or chemotherapeutic agents were administered alone
for 24h before administration of the second drug. The
treatment schedule with CLFF preceding chemotherapeutic
agents showed a similar synergistic growth inhibitory eﬀect
to the simultaneous treatment regimen. By contrast, largely
antagonistic eﬀects were seen in both two cell lines when
cells were treated with the reverse sequence (Figure 3).
The results suggested that the simultaneous treatment and
administration of CLFF followed by chemotherapeutic agent
treatments were better than the reverse sequence treatment.
3.3. Apoptosis Eﬀects Mediated by CLFF and Chemotherapeu-
ticAgents. To conﬁrm whether CLFFpluschemotherapeutic
agents could increase the cell death by inducing apoptosis,
ﬂow cytometric analysis was performed to betterunderstand
the apoptosis eﬀects of combining CLFF and chemothera-
peutic agents. The double staining with both Annexin-V-
FITC and PI was employed to distinguish the apoptotic cells
from others. SGC-7901 and BGC-823 cell lines were treated
with CLFF and anticancer drugs singly and in combination.
The doses of agents chosen were close to their respective
50% inhibitory concentrations(IC50).The percentageof the
apoptoticcellsproducedby the individual chemotherapeutic
agents was signiﬁcant increased by the presence of CLFF,
indicating that the simultaneous treatment of CLFF and
anticancer drugs induced apoptotic in a synergistic manner
(Figure 4). Especially, the percentages of the apoptotic cells
(early apoptosis plus late apoptosis) induced by CLFF and 5-
FUwere(8.4+6.8),(24.6+4.6)%inSGC-7901cellsand(6.7
+ 1.4), (12.6 + 3.8)% in BGC-823 cells, while the percentage
of them induced by drug combination in both cell lines were
increased to (80.5 + 12.9) and (66.1 + 6.4)%, respectively.
3.4. CLFF Inﬂuence mRNA Expression of Chemotherapeutic
Agent Resistance-Related Genes. In an attempt to explain the
mechanisms underlying the synergistic interaction between
CLFF and chemotherapeutic agents, we hypothesized that
CLFF might aﬀect the expression of the investigated
chemotherapeuticagentresistance-related genes,i.e.excision
repair cross-complementing (ERCC1), thymidylate synthase
(TS), class III β-tubulin (β-tubulin III) and tau, in gastric
cancers, inﬂuencing sensitivity to those drugs. After incu-
bation with CLFF and every chemotherapeutic agent singly
a tt h e i rr e s p e c t i v eI C 4 0o ri nc o m b i n a t i o nf o r2 4h ,m R N A
expressions ofthese genesin SGC-7901cellswere assessed by
quantitative RT-PCR. As shown in Figure 5, the expression
levels of ERCC1, TS, β-tubulin III and tau were signiﬁcantly
down-regulated after treatment with CLFF alone or CLFF
combined with chemotherapeutic agents. However, any of
chemotherapeutic agents alone did not down-regulate their
respective drug resistance-associated genes, and the expres-
sion levels of ERCC1 were even signiﬁcantly up-regulated by
Oxa. Moreover, we also compared the expression levels of
chemotherapeutic agent resistance-associated genes between
SGC-7901 cells and BGC-823 cells. The results showed that
theexpressionlevelsofTS,β-tubulinIIIandtauinSGC-7901
cells were lower than those in BGC-823 cells (P < .05), while
the expression level of ERCC1 was higher than that in BGC-
823 cells (P < .01).
4.Discussion
Active combination chemotherapy has the potential to
decrease drug doses, reduce toxicity, and help to overcome
the problemof drug resistance. The objective ofthis report is
to investigate whether the antitumor activity of chemother-
apeutic agents commonly used in gastric cancer could
be enhanced by CLFF, a Chinese herb medicine formula.
First, we evaluated the nature of the interaction between
CLFF and every chemotherapeutic agent using media-eﬀect
analysis. Our ﬁndings indicate simultaneous treatment and
administration of CLFF followed by chemotherapeuticagent
treatments could result in a synergistic interaction between
CLFF and series of chemotherapeutic agents for two gastric
cancer cell lines. Especially, CLFF had a more intensive
synergistic eﬀect on the cytotoxicity of 5-FU. Then we found
the combination of CLFF and chemotherapeutic agents
could also induce apoptosis in a synergistic manner. At last,
we found that the expression of chemotherapeutic agent
resistance-related genes was down-regulated by CLFF alone
and CLFF combination with chemotherapeutic agents. Our
results suggested CLFF appeared a promising candidate for
combiningwith threechemotherapeuticagents.Thepossible
mechanisms might be partially due to the down-regulation
of chemotherapeutic agent resistance related genes and the
synergistic apoptotic eﬀect.
Herbal medicine formulae as CAM have been accepted
by more and more cancer patients in China [8], and its
popularity outside China is also undeniable [15]. Many
cancer patients had been taking herbal medicine before
starting chemotherapy or during chemotherapy. The rea-
sons cited for using CAM in cancer patients included
immunomodulation, survival prolongation, quality of life
(QOL), reduction of treatment-related toxic eﬀects [5, 6].
Clinical observation found some herbal medicine formulae
could improve the outcomes of chemotherapy [16], yet the
potential mechanism has not been explained by modern
science. Previous studies have demonstrated that many
plant-derived compounds have the potential in sensitizing
the tumor cells to chemotherapeutic agents or restoring
the sensitivity of some drug resistant cells [17]. However,
we did not know whether the herbal medicine formulae
could sensitize the tumor cells to chemotherapeutic agents.
In this study, we observed the interaction between CLFF
and chemotherapeutic agents in two gastric cancer cell lines
using media-eﬀect analysis. Overall, in low dose inhibition
range, CLFF had synergistic eﬀects on the cytotoxicity of
all three drugs, suggesting CLFF at least could sensitize the
two gastric cancer cell lines to these three chemotherapeutic
agents. Similar experiments couldbe carried out in othercell
lines to evaluate further the potential of such combinations
against diﬀerent types of tumor cells.Evidence-Based Complementary and Alternative Medicine 9
Currently, it remains unclear to agree with the standard
care in gastric cancer treatment. 5-FU, Oxa and Doc
represent the most powerful classes of anticancer agents,
and triple combinations containing 5-FU has been wide
used in gastric cancer management over the past few years
[18]. 5-FU-Oxa combinations in numerous phase II studies
for advanced gastric cancer have shown response rates and
progression free survival (PFS) ranging from 38 to 55%
and 5–7 months, respectively [19], and docetaxel has also
been shown to be active against advanced gastric cancer as
ﬁrst-line treatment, in combination with 5-FU and cisplatin
[20]. 5-FU and Oxa could induce DNA damage directly
or indirectly [21, 22], and induced apoptosis predominatly
by p53-dependent pathway [23], while Doc induce cell
death predominantly via p53-independent pathway [24],
such as caspase-dependent pathway. Results of apoptosis
analysis here indicated the simultaneous treatment of CLFF
and anticancer drugs induced apoptosis in a synergistic
manner, which at least in part explain the synergy eﬀects
of CLFF in combination of these three drugs. However, the
mechanism of CLFF increasing of chemotherapy agents-
induced apoptosis need to be further explored by speciﬁc
studies on apoptosis.
Many experimental studies performed on various can-
cers have demonstrated that overexpression of chemother-
apy agent resistance-related genes is associated with their
corresponding drug resistance. TS is the DNA synthesis
enzyme that is targeted by 5-FU treatment and plays a very
important part in the eﬃcacy of 5-FU. High TS expression
level is reported to contribute to a resistance to 5-FU
and poor clinical outcome [25, 26]. Cisplatin and other
cancer chemotherapeutic agents cause monoadducts and
intrastrand or interstrand cross-links in DNA [27]. The
removal of adducts from genomic DNA is mainly mediated
by the nucleotide excision repair (NER) pathway for the
repair of interstrand cross-links [28, 29]. ERCC1 plays a
crucial role in NER and has been reported to inﬂuence the
eﬀectiveness of cisplatin-based therapy for gastric and other
cancers in a negative manner [30, 31]. ERCC1 has been
shown to be an independentprognostic marker ofplatinum-
based chemotherapy [32]. Of the various microtubule-
associated molecules, β-tubulin III and tau have been
reported to be closely associated with the therapeutic
eﬃcacy of taxane-based chemotherapy. Preclinical studies
indicate that overexpression of β-tubulin III is associated
with resistance to tubulin-binding agents [33], and low tau
mRNA expression correlates with sensitivity to paclitaxel in
vitro [34]. Inhibition of tau function could be explored as
a potential therapeutic strategy to increase the anticancer
activity of paclitaxel [35]. In the present study, we initially
found the levels of TS, β-tubulin III and tau mRNA in
SGC-7901 cells were lower than those in BGC-823 cells,
while the levels of ERCC1 mRNA in SGC-7901 cells were
higher than that in BGC-823 cells, which might explain
why SGC-7901 cells are more sensitive to 5-FU and Doc,
while BGC-823 cells are more sensitive to oxaliplatin. We
further found that TS, ERCC1, β-tubulin III and tau mRNA
were signiﬁcantly down-regulated by CLFF alone or CLFF
combination with chemotherapeutic agents, while any of
chemotherapeutic agents alone did not down-regulate their
respective drug resistance-associated genes, which might
explain why CLFF could sensitize 5-FU, Oxa and Doc,
and why synergistic eﬀects of simultaneous treatment and
administration of CLFF preceding chemotherapeutic agents
diﬀer from the reverse schedule. The mechanisms of CLFF
inﬂuencing these gene expressions remain to be less clear,
and the possible mechanisms may be involved in changes
of many signal transduction pathways associated with drug–
gene interaction, which need further to be studied by
analysis of diﬀerences in gene expression proﬁles of diﬀerent
pathways in our future works.
In conclusion, this study has demonstrated that com-
bination of CLFF and a series of chemotherapeutic agents
could result in a useful synergistic interaction against gastric
cancer, and CLFF has considerable promise as an adjuvant
to chemotherapy. Its potential mechanism would be their
synergistic eﬀects on apoptosis and the down-regulation
of chemotherapeutic agent resistance related genes. Further
studies should be studied in vivo.
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